Detalhe da pesquisa
1.
Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura.
Ann Hematol
; 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38671298
2.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38012435
3.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37354090
4.
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension.
Ann Hematol
; 102(10): 2717-2723, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603060
5.
Systematic Review and Meta-Analysis of Health-Related Quality of Life in Patients with ß-Thalassemia that Underwent Hematopoietic Stem Cell Transplantation.
Clin Pract Epidemiol Ment Health
; 19(Suppl-1): e174501792301031, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38659631
6.
Understanding the User's Point of View: When the Doctor Gets Sick with Cancer and Seeks Help.
Clin Pract Epidemiol Ment Health
; 19: e17450179241325, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164454
7.
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy.
Ann Hematol
; 101(4): 749-754, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35098366
8.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388860
9.
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Acta Haematol
; 144(3): 322-326, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32892194
10.
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Clin Pract Epidemiol Ment Health
; 17(1): 264-270, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35444710
11.
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.
Clin Pract Epidemiol Ment Health
; 17(1): 307-314, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35444708
12.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474619
13.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30892724
14.
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Ann Hematol
; 98(8): 1885-1890, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044260
15.
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.
Ann Hematol
; 101(4): 929-931, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34302519
16.
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.
Hematol Oncol
; 38(4): 607-610, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602167
17.
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia.
J Clin Med
; 13(1)2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38202280
18.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Am J Hematol
; 93(7): E159-E161, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29633312
19.
Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules.
Front Oncol
; 13: 1239042, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38260856
20.
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with ß-Thalassemia after Splenectomy.
J Clin Med
; 12(7)2023 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37048630